IDH1‐mutated Crohn's disease‐associated small bowel adenocarcinomas: Distinctive pathological features and association with MGMT methylation and serrated‐type dysplasia
- Creators
- Guerini, Camilla
- Furlan, Daniela
- Ferrario, Giuseppina
- Grillo, Federica
- Libera, Laura
- Arpa, Giovanni
- Klersy, Catherine
- Lenti, Marco V
- Riboni, Roberta
- Solcia, Enrico
- Fassan, Matteo
- Mastracci, Luca
- Ardizzone, Sandro
- Moens, Annick
- De Hertogh, Gert
- Ferrante, Marc
- Graham, Rondell P
- Sessa, Fausto
- Paulli, Marco
- Di Sabatino, Antonio
- Vanoli, Alessandro
- Others:
- Guerini, Camilla
- Furlan, Daniela
- Ferrario, Giuseppina
- Grillo, Federica
- Libera, Laura
- Arpa, Giovanni
- Klersy, Catherine
- Lenti, Marco V
- Riboni, Roberta
- Solcia, Enrico
- Fassan, Matteo
- Mastracci, Luca
- Ardizzone, Sandro
- Moens, Annick
- De Hertogh, Gert
- Ferrante, Marc
- Graham, Rondell P
- Sessa, Fausto
- Paulli, Marco
- Di Sabatino, Antonio
- Vanoli, Alessandro
Description
Aims: Patients with Crohn's disease (CrD) have an elevated risk for the development of small bowel adenocarcinomas (SBAs). Actionable isocitrate dehydrogenase 1 (IDH1) mutations have been reported to be more frequent in CrD-SBAs than in sporadic SBAs. The present study aimed to investigate the clinicopathological and immunophenotypical features, as well as methylation profiles, of IDH1-mutated CrD-SBAs.Methods and results: An international multicentre series of surgically resected CrD-SBAs was tested for IDH1 mutation. Clinicopathological features, immunophenotypical marker expression and O6-methylguanine-DNA methyltransferase (MGMT) and long interspersed nuclear element-1 (LINE-1) methylation were compared between IDH1-mutated and IDH1 wild-type CrD-SBAs. Ten (20%) of the 49 CrD-SBAs examined harboured an IDH1 mutation and all the mutated cancers harboured the R132C variant. Compared to IDH1 wild-type cases, IDH1-mutated CrD-SBAs showed significantly lower rates of cytokeratin 7 expression (P = 0.005) and higher rates of p53 overexpression (P = 0.012) and MGMT methylation (P = 0.012). All three dysplastic growths associated with IDH1-mutated SBAs harboured the same IDH1 variant (R132C) of the corresponding invasive cancer, and all were of non-conventional subtype (two serrated dysplastic lesions and one goblet cell-deficient dysplasia). In particular, non-conventional serrated dysplasia was significantly associated with IDH1-mutated CrD-SBAs (P = 0.029). No significant cancer-specific survival difference between IDH1-mutated CrD-SBA patients and IDH1 wild-type CrD-SBA patients was found (hazard ratio = 0.55, 95% confidence interval = 0.16-1.89; P = 0.313).Conclusions: IDH1-mutated CrD-SBAs, which represent approximately one-fifth of total cases, are characterised by distinctive immunophenotypical features and methylation profiles, with potential therapeutic implications. Moreover, IDH1-mutated non-conventional, serrated dysplasia is likely to represent a precursor lesion to such CrD-SBAs.
Additional details
- URL
- https://hdl.handle.net/11567/1201355
- URN
- urn:oai:iris.unige.it:11567/1201355
- Origin repository
- UNIGE